AN02

AN02 is a derivative of Curcumin (HY-N0005) . AN02 inhibits the proliferation and clonogenicity, migration and invasion of ovarian cancer cells. AN02 dose-dependently upregulates the expression of APC and mediates the degradation of CTLA-4 through SMAD4. In the small xenograft model, AN02 significantly inhibits tumor growth and reverses the tumor immune-suppressive microenvironment. AN02, when combined with Ipilimumab (HY-P9901), can enhance efficacy and inhibit epithelial-mesenchymal transition. AN02 can be used for the study of ovarian cancer[1].

Product Specifications

CAS Number

[1246964-08-8]

UNSPSC

12352005

Target

CTLA-4; TGF-beta/Smad

Related Pathways

Immunology/Inflammation; Stem Cell/Wnt; TGF-beta/Smad

Field of Research

Cancer

Smiles

ClC1=CC=CC=C1/C=C(C/2=O)\CNCC2=C/C3=C(Cl)C=CC=C3

Molecular Formula

C19H15Cl2NO

Molecular Weight

344.23

References & Citations

[1]Jin H, et al. AN02, a Naovel Curcumin Derivative, Orchestrates APC-SMAD4-Mediated CTLA-4 Degradation for Ovarian Cancer Therapy. Mol Carcinog. 2025 Oct 21.